Vaxart Stock Should Rebound After 25% Decline Over The Last Month
- Thursday, April 1, 2021, 7:13
- Market
- Add a comment
Vaxart stock has declined by around 25% over the last month and currently trades at about $5.80 per share. While the recent sell-off in the clinical stage biotech is due to broader correction in technology and biotech names, Vaxart stock has come under pressure since early February when the company.
About the Author
admin123 has written 23402 stories on this site.
